

# SEED TO CONSUMER CBD YOU CAN TRUST



**SATIVA  
WELLNESS  
GROUP**

TM



# DISCLAIMER

This confidential presentation (together with the accompanying oral presentation, “Presentation”) is being provided to you (the “Recipient”) by Sativa Wellness Group Inc. (the “Company”) for information purposes only. This Presentation does not constitute and has not been approved by an authorised person as, a "financial promotion" within the meaning in section 21 of the Financial Services and Markets Act 2000. This Presentation is not a prospectus or an admission document or an advertisement and does not constitute or form part of, and should not be construed as, an offer or invitation to sell or any solicitation of any offer to purchase or subscribe for any common shares of the Company (“Shares”) in any jurisdiction. Such an offer and solicitation only may be made pursuant to the private subscription documents and other applicable documents (the “Operative Documents”), which should be read in their entirety. The statements in this Presentation are not intended to be complete or final and are qualified in their entirety by reference to the Operative Documents. In the event that the descriptions or terms described herein are inconsistent with or contrary to the descriptions in or terms of the Operative Documents, the Operative Documents shall control. Therefore, any recipient hereof should read the Operative Documents and should conduct its own independent analysis of the date referred to herein. Neither the Presentation, nor any part of it nor anything contained or referred to in it, nor the fact of its distribution, should form the basis of or be relied on in connection with or act as an inducement in relation to a decision to purchase or subscribe for or enter into any contract or make any other commitment whatsoever in relation to any Shares. Reliance on this Presentation for the purpose of engaging in any

investment activity may expose an individual to a significant risk of losing all of the property or other assets invested. Whilst the Presentation has been prepared in good faith, no representation or warranty, express or implied, is given by or on behalf of the Company, its respective directors and affiliates or any other person as to the accuracy or completeness of the information or opinions contained in this Presentation and no responsibility or liability whatsoever is or will be accepted by the Company, its directors and affiliates or any other person for any loss howsoever arising, directly or indirectly, from any use of such information or opinions or otherwise arising in connection therewith. Any such liability is expressly disclaimed, save that nothing in this Presentation Disclaimer shall be effective to limit or exclude any liability for fraud or which otherwise cannot, by law or regulation, be so limited or excluded. The promotion of Shares and the distribution of this Presentation in the United Kingdom and elsewhere are restricted by law. Accordingly, you must not copy, publish or distribute this Presentation in any way or to any person in or into any jurisdiction. The Company is not responsible to the Recipient for providing regulatory and legal protections afforded to customers (as defined in the rules of the Financial Conduct Authority) nor for providing advice in relation to the contents of this Presentation on any matter, transaction or arrangement referred to in it. Neither the Company nor any of its directors, officers or employees makes any representation or warranty, express or implied, as to the accuracy or completeness of the information or opinions contained in this Presentation. To the fullest extent permitted by law, neither the Company nor any of its members, directors, officers, employees, agents or

representatives nor any other person accepts any liability whatsoever for any errors, omissions or inaccuracies in such information or opinions or for any loss, cost or damage suffered or incurred howsoever arising, directly or indirectly, from any use of this Presentation or its contents or otherwise in connection with its subject matter. You should always seek your own independent advice about investment and tax matters from a suitably qualified and authorised independent financial adviser. You should note that neither the Company nor any of its members, directors, officers, employees, agents or representatives is authorised to give tax or financial advice. Nothing in this Presentation is, or should be relied on as, a promise or representation as to the future. This Presentation contains forward-looking statements” or “forward-looking information” within the meaning of applicable securities laws (collectively, “forward-looking statements”), which reflect the views of the Company with respect to, among other things, the Company’s operations. These forward-looking statements are identified by the use of words such as “believe”, “expect”, “potential”, “continue”, “may”, “will”, “should”, “seek”, “approximately”, “predict”, “intend”, “plan”, “estimate”, “anticipate” or other comparable words. These forward-looking statements are subject to various risks, uncertainties and assumptions. There are or will be important factors that could cause actual outcomes or results to differ materially from those indicated in these statements. Should any assumptions underlying the forward-looking statements contained in this Presentation prove to be incorrect, the actual outcome or results may differ materially from outcomes or results projected in these statements. The Company is under no obligation to update or review any

forward-looking statement, whether as a result of new information, future developments or otherwise, except as required by applicable law or regulation. The Presentation may have been sent to you in an electronic form. You are reminded that documents transmitted via this medium may be altered or changed during the process of electronic transmission. You are responsible for protecting against viruses and other destructive items. Your receipt of this electronic transmission is at your own risk and it is your responsibility to take precautions to ensure that it is free from viruses and other items of a destructive nature. As a consequence of the above, neither the Company nor any director, officer, employee or agent of any of them or any affiliate of any such person accepts any liability or responsibility whatsoever in respect of any difference between the document distributed to you in electronic format and the hard copy version that may be made available to you.

Resale Restrictions: The securities described herein are being offered on a private placement basis in reliance upon prospectus and registration exemptions under applicable securities legislation. Resale of the securities offered hereby will be subject to restrictions under applicable securities legislation, which will vary depending on the relevant jurisdiction. Generally, such securities may be resold only pursuant to an exemption from the prospectus and registration requirements of applicable securities legislation or pursuant to an exemption order granted by appropriate securities regulatory authorities.



**THE #1 CONSUMER  
CONCERN IS  
TRUST AND  
SAFETY IN THEIR  
CBD PRODUCTS**

While other companies claim to "control the supply chain," Sativa owns the entire supply chain.



THE SATIVA DIFFERENCE



CSE:SWEL






THE SATIVA DIFFERENCE

# SEED TO CONSUMER INTEGRATION


SATIVA  
WELLNESS  
GROUP



stillcanna

## Extraction

Proprietary extraction techniques that set the standard for quality.



PHYTOVISTA  
LABORATORIES



## Manufacturing

State of the art product development and white labeling services.

GOODBODY  
BOTANICALS



GOODBODY  
HEMP

GOODBODY  
WELLNESS



## Sales Channels

Retail and wholesale channels designed for today's fast evolving consumer expectations.

GOODBODY  
STORE.COM

WHOLE  
SALE

## Cultivation

By far the largest hemp cultivator in Poland and one of the largest in Europe.



stillcanna

## Quality Control

The UK's premier testing facility for CBD and hemp-based products.

GOODBODY



GOODBODY  
CORPORATE SANITISATION SOLUTIONS

Tessellate  
Collective

CSE:SWEL




## MARKET OPPORTUNITY

**THE EUROPEAN CBD  
MARKET IS EXPECTED  
TO GROW 400% BY  
2023 WITH A TOTAL  
VALUE OF \$1.7 BILLION**


Source: [www.brightfieldgroup.com/press-releases/europe-cbd-market-through-2023](http://www.brightfieldgroup.com/press-releases/europe-cbd-market-through-2023)

3 out of 4 consumers report that CBD use has positively impacted their lives while 65% of current CBD users are likely to buy CBD again in the next 6 months.



Source: [www.healtheuropa.eu/applying-data-address-europes-burgeoning-cbd-market/98012/](http://www.healtheuropa.eu/applying-data-address-europes-burgeoning-cbd-market/98012/)

Non-consumers list factors like product quality and being able to ask for advice on products among the top reasons influencing their potential CBD purchases.







## SAFETY AND TRUST

# A BOOMING UNREGULATED INDUSTRY



**“CBD LABELING WHAT  
YOU SEE IS NOT ALWAYS  
WHAT YOU GET”**

[Read Article](#)



**“FEARS TOXIC CANNABIS  
POLLUTED IN CHINA COULD  
FLOOD UK SEED MARKET”**

[Read Article](#)

Recent FDA product testing showed that only **45% of products contained the amount of CBD as advertised**, and **49% of all products tested had higher than allowable levels of THC**. Even more surprising was that many brands contained no CBD whatsoever, while some others also tested positive for toxic substances.



**“FDA WARNS 15 COMPANIES  
FOR ILLEGALLY SELLING  
VARIOUS CBD PRODUCTS”**

[Read Article](#)



**“WHAT'S IN YOUR CBD?  
BUYER BEWARE”**

[Read Article](#)

**SATIVA  
WELLNESS  
GROUP**

**SAFETY AND TRUST**

# THE SATIVA ANSWER

**Complete control of the entire supply chain from seed to consumer** is the only way to produce consistent, high-quality products. With the cultivation and extraction of all cannabinoids, fully operational

state-of-the-art cannabis testing laboratories, established brands, and existing wholesale and retail sales channels Sativa Wellness is **well-positioned to thrive in a mature, more regulated market.**



Complete traceability of all cannabinoids from seed to consumer



All processes performed in certified, safe, state-of-the-art facilities



All products thoroughly laboratory tested for consistency, purity and safety

Pending government legislation on labelling and product testing will reduce the number of brands significantly.







## CULTIVATION

# IT STARTS WITH A SEED

### Current Unregulated Industry

- ✗ Hemp modified seeds, fertilizers, and pesticides in untested soil.
- ✗ Hemp biomass with illegal THC levels, pesticides, and heavy metals make it in to the production cycle and onto the shelves.
- ✗ Recent testing has shown "most of the cultivars and biomass grown using most of the varieties that we're currently using in the U.S. would no longer be defined as hemp."

### The Sativa Difference

- ✓ Hemp grown exclusively on certified organic land tested to be free of heavy metals, pesticides, and within legal THC limits.
- ✓ Testing of biomass in certified laboratories during growth and after harvest.
- ✓ Tracking of biomass through chain of custody from our fields to consumers' homes.



Sativa is ahead of the expected global agriculture testing and compliance standards.

stillcanna 

CSE:SWEL






Sativa is ahead of the anticipated global legislation on certification and health requirements for cannabinoid extraction facilities.



## EXTRACTION

# EXTRACTING PURE EXCELLENCE

SATIVA  
WELLNESS  
GROUP



### Current Unregulated Industry

- ✗ Many small and sizeable unlicensed extraction facilities are using carcinogenic solvents as their primary method, including Butane and Benzene.
- ✗ Unregulated and unlicensed extraction facilities do not mandate mandatory product testing throughout the extraction process and have no certifiable standard operating procedures.
- ✗ This results in impure, untested products in consumers' hands, which are mislabeled and potentially even dangerous.

### The Sativa Difference

- ✓ Initial extraction using grain alcohol in a licensed, inspected facility adhering to food safety standards under Hazard Analysis and Critical Control Point (HACCP) certification.
- ✓ Tracking and laboratory testing of the product in every step of the process from biomass to finished CBD.
- ✓ Resulting in a safe, pure, consistent product in consumers' hands.

  
stillcanna





## TESTING & MANUFACTURING

# MANUFACTURING & QUALITY CONTROL

### Current Unregulated Industry


- ✗ Of the thousands of brands of CBD, only a handful make their own consumer products, many smaller players mix and bottle in non-sterile kitchen, garages and basements with no required testing.
- ✗ Only a few CBD providers laboratory test their finished products before selling to an unsuspecting consumer.
- ✗ Less than 50% of industry products provide what is promised on the label.

### The Sativa Difference


- ✓ Testing of all products for purity, safety and consistency in our own industry-recognized, certified laboratory, PhytoVista.
- ✓ State-of-the-art food-safe bottling facility which formulates Sativa brands as well as provides white-label services to other brands.



PHYTOVISTA  
LABORATORIES



Sativa is ahead of the anticipated global legislation on testing and health requirements for a Cannabinoid formulation and packaging facility.







## ★ BRANDS

# BRANDS YOU CAN TRUST

### Current Unregulated Industry

- ✗ A large number of unregulated and unlicensed products sold through the Internet make illegal health claims about their product.
- ✗ There is still no clear brand leader, while many products have no physical presence and sell online only.
- ✗ High product cost equates to high retail cost, CBD becomes unaffordable for many consumers.

### The Sativa Difference

- ✓ Products that meet or exceed current regulations with advanced stage Novel Food licencing (a requirement in many E.U. countries past March 2021)
- ✓ Ownership of some of the most recognized brands in Europe with retail presence and distribution in place.
- ✓ Owning the entire supply chain enables the lowest possible cost of goods in the industry and can be used to price a competitive advantage in the marketplace.





# FROM A TRUSTED SOURCE

## Current Unregulated Industry


- ✗ In an unregulated marketplace, we are seeing untested, impure bulk CBD sold globally. In Europe only CBD from European approved hemp is legally allowed to be sold.
- ✗ Many companies are buying Chinese and American bulk CBD and passing it off as European product.
- ✗ Many larger established businesses investigate bulk "chain of custody" to assure they are purchasing a compliant product.

## The Sativa Difference

- ✓ Fully compliant cannabis cultivation and those of approved agricultural partners produce legal and traceable wholesale CBD products.
- ✓ CBD products that are compliant with all European laws from seed to consumer
- ✓ As governments begin to enforce current regulations Sativa will benefit through its current and ongoing compliance







## RETAIL

# OWNED SALES CHANNELS



### Current Unregulated Industry

- ✗ Loose and unenforced packaging requirements lead to inferior products on the shelf.
- ✗ Many products have no testing, no return policy, and no stability as brands come and go daily.

### The Sativa Difference

- ✓ Consumer confidence in recognized, stable brands with retail outlets and distribution in well-known pharmacies, wellness and retail outlets.
- ✓ Addressing the move towards the preference for online purchasing, we have launched goodbodystore.com. The e-commerce site houses Goodbody and supplementary brands through an innovative "Pillars" structure designed to flow consumers to areas of need.
- ✓ Our flagship store is set up for a franchise model with scalable infrastructure.







2020-2021

# CATALYSTS







## 2020-2021 CATALYSTS

# CULTIVATION

### Sativa, from lessons learned in 2019, has taken a diversified approach to agriculture:

- Along with our own certified organic crops, we've partnered with hemp growers throughout Europe.
- The company expects to have access to 450,000 kilos of high-grade biomass with a gross CBD content of 225 million grams.
- This multipronged approach reduces or eliminates agricultural risk while assuring the highest quality certified CBD biomass available in Europe.
- The company has to date secured more high-quality biomass than any in Europe at very competitive pricing.



CSE:SWEL





## Proprietary extraction techniques that set the standard for quality.

- Two completed extraction facilities: Origin in Romania and Nexus in Poland, are each capable of producing up to 1000 finished Kilos of CBD monthly.
- The company feels combined with its cost of biomass and cost of manufacturing it will be able to produce the lowest cost CBD in Europe.
- We believe Kosher, HACCP, and Novel Foods certifications combined with already low production costs will enable us to dictate the bulk pricing of CBD in Europe.

2020-2021 CATALYSTS

# EXTRACTION

SATIVA  
WELLNESS  
GROUP

stillcanna 



CSE:SWEL





2020-2021 CATALYSTS

# QUALITY CONTROL

**It is anticipated that mandatory testing will become one of the most significant single global events across the cannabis industry.**

- Sativa's Phytovista laboratory is already a recognized, trusted and certified laboratory to the cannabis industry in Europe.
- Additionally, Sativa has ownership of its laboratory, so our owned brands receive priority testing enabling us to bypass potential backlogs and minimize costs.
- With product testing expected to become mandatory, Sativa expects to see a substantial increase in testing enquiries and business.



CSE:SWEL

PHYTOVISTA  
LABORATORIES



**The majority of brands do not formulate their own products or own anything. They come to companies like Sativa for their product.**



- As Novel Food certification is required for many countries beyond March 2021 only a handful of manufacturers like Sativa will be able to offer this certification.
- The company anticipates a sharp increase in white label orders, as brands will start to seek compliant manufacturers to keep their brands on the shelf.
- Now, with the ability to offer third-party clients all services from seed to consumer in a compliant, low-cost, and safe manner, the company expects increased manufacturing revenue that generally goes hand in hand with its White Labelling.



2020-2021 CATALYSTS

# MANUFACTURING



CSE:SWEL





## 2020-2021 CATALYSTS BRANDS



### Product Line Expansion:

- Alongside our recently launched CBD oils with Vitamin D, there are plans to expand the product range further.
- The expansion of the product range will ensure that we have the biggest range on offer to retailers and consumers UK wide.
- The product range will also enable us to strengthen our wellness offering for marketing collateral.




CSE:SWEL





# SALES CHANNELS

## Focus: Accelerating Online Growth







## 2020-2021 CATALYSTS

# WHOLESALE

**Owning the entire supply chain from seed, Sativa will see one of its most significant benefits in the bulk CBD business:**

- Sativa is unaware of any other company in the industry that owns the entire supply chain. They may claim they control it through third-party contracts, but this is far different than outright ownership.
- With the lowest costs in all phases of CBD production, the company feels it will be able to dictate the pricing of bulk CBD and become one of Europe's leading suppliers.





## 2020-2021 CATALYSTS

# MERGERS AND ACQUISITIONS

While concentrating on organic growth, the company also intends to leverage its strong position to look at growth through acquisitions. The company feels the current global cannabis economy, along with the emergence of COVID-19, has created some well-priced opportunities.

Although the company has concentrated in CBD, it does have a medical THC handling permit and does grow a relatively small amount of marijuana for medical research purposes. Should the business opportunity arise and make sense, the company may increase its involvement in the medical marijuana space.



CSE:SWEL



# PEER COMPARABLES



Company	CULTIVATION	EXTRACTION	LABORATORY	MANUFACTURING	BRANDS	SALES CHANNELS	
						Wholesale	Retail
Sativa Wellness	✓	✓	✓	✓	✓	✓	✓
Dragonfly	✓				✓		✓
Charlotte’s Web	✓	✓		✓	✓		✓
Mile High Labs		✓	✓	✓			✓
Isodiol	✓	✓			✓		✓
Endoca	✓	✓	✓		✓		✓
CV Science	✓	✓		✓	✓		✓




\* based on publically available information



# LICENCING STRATEGY

SATIVA  
WELLNESS  
GROUP



Engaged with:





# LEADERSHIP TEAM

## BOARD OF DIRECTORS



**JONATHAN WEARING**  
Non-Executive Chairman



**HENRY LEES-BUCKLEY**  
Chief Executive Officer



**JOSEPH COLLIVER**  
Chief Financial Officer



**JASON DUSSAULT**  
Non-Executive Director,  
Corporate Communications



**ANGUS KERR**  
Non-Executive Director



**MARK BLOWER**  
Non-Executive Director



**ANNE TEW**  
Corporate Secretary







# COMBINED SHARE STRUCTURE

STILLCANNA	
Undiluted Issued and Outstanding	111,874,727*
Outstanding Warrants (Average strike price \$1.40)	15,174,425*
Outstanding Options	3,635,000*
SATIVA WELLNESS	
Undiluted Issued and Outstanding	190,720,026
Outstanding Warrants (Average strike price \$xx)	10,328,631 (Average strike price = \$0.25)
Outstanding Options	39,793,377
Fully Diluted Issued & Outstanding	371,526,206





CSE:SWEL

Tel: 02079711255  
enquiries@  
sativawellnessgroup.com

The Blue Building  
Stubbs Lane  
Beckington, BA11 6TE



# APPENDIX





# BOARD DIRECTOR BIOS

**JONATHAN WEARING**  
Non-Executive Chairman

Jonathan joins as non-Executive Chairman. Jonathan is an experienced, City-based corporate financier, who began his City career after graduating from Cambridge University with a M.A. in Economics. He was Chairman of Ideagen plc on its admission to the AIM market in July 2012 until April 2018. Following eight years in Citibank London’s corporate banking division, providing debt finance for growth and acquisition purposes, he moved to Citicorp’s London investment bank (CIBL) where, as a Director in the Corporate Finance Department, he worked on both UK and cross-border transactions.

**HENRY LEES-BUCKLEY**  
CEO

Chief Executive Officer of Sativa Group PLC, is a seasoned corporate executive, with extensive experience of leading companies in the public markets. Henry was previously CEO of Uni-Select [TSX:UNS], a Canadian TSX quoted company, with operations in the UK, Canada and the USA. Prior to that, he was a senior global executive and officer in the USA and Canada for W.W. Grainger, a US\$15 billion market capitalisation Fortune 500 company. Henry is currently a non-Executive Director of NASDAQ-quoted BMC (Building Materials Corp) [NASDAQ:BMCH] which has sales of US\$3.8 billion and a market capitalisation of US\$1.6 billion. Henry holds an MBA from Queens University, Kingston, Ontario and has held numerous executive level positions both in North America and the United Kingdom.

**JOSEPH COLLIVER**  
CFO

Joseph is a qualified Chartered Accountant with significant commercial finance experience. Before joining Sativa, Joseph was a Director of Consulting at Kantar Consulting, part of WPP plc (“WPP”) which advises Retail, Sales and Shopper clients on enhancing their commercial capability and the commercial competency of their staff. Prior to this, Joseph was Chief Financial Officer and a senior board member at WPP’s Kantar Futures, which advises its clients on enhancing profit through change and shaping strategy. Here, Joseph was accountable for financial performance, managing a global finance team. From 2012-2015 Joseph was Global Commercial Director of WPP’s Kantar subsidiary Taylor Nelson Sofres, a \$1.8 billion turnover marketing agency.

**JASON DUSSAULT**  
Non-Executive Director, Corporate Communications

A multi-talented man, known for his innovative marketing style, and as an accredited artist. A man of great accomplishments, he was the star and producer of the Dussault Inc. a City TV reality show. Dussault has received significant media attention on FOX NEWS, Entertainment Tonight, CityTV, ETalk on CTV, CBC, MTV, The Wall Street Journal and New York Times to name a few. Jason is well versed in the capital markets and mining, with decades of experience in the North West Territories diamond boom. Over the past several years he has pushed the global frontier in the Cannabis marketplace as CEO of Stillcanna Inc. a Canadian public company focused on manufacturing CBD in Europe. He raised over 30 million dollars, built large extraction facilities in Romania and Poland, built an experienced global team and negotiated significant strategic alliances including the merger with Sativa.

**ANNE TEW**  
Company Secretary

Anne is an experienced Accountant, Corporate Secretary and professional business mentor with over 30 years’ experience across a range of industries including the NHS, testing laboratories, manufacturing and farming. She has successfully led projects to achieve business turnaround, restructuring, growth and development. Anne has worked as an Executive and Non-Executive Director as well as advising board members in financial and governance matters as the Corporate Secretary or as an external consultant.

**MARK BLOWER**  
Non-Executive Director

Mark is an experienced finance professional, having spent the last 20 years actively overseeing the financial performance of over 70 UK SME’s, with a particular focus on raising debt and private equity. He began his career in 1996 at the Investment Banking division of a large UK bank, before joining NM Rothschild in 2000. He then ran a highly successful leveraged debt team for another UK lending institution for five years before starting his Private Equity career in 2010. During his career to-date he has held a number of board positions, across a variety of sectors.

**ANGUS KERR**  
Non-Executive Director

Angus is an adviser and capital markets professional with nearly 25 years’ experience in global banking with specific expertise in strategic and equity advisory, M&A and ECM. He has held, inter alia, managing director and management roles covering advisory, equity advisory and ECM at a number of organisations, including head of Mid-Market Advisory and Broking at Credit Suisse and head of UK ECM Dresdner Kleinwort. He has a long track record of advising companies and high-profile individuals in the UK, USA and Europe. Prior to his career in finance Angus was an Army Officer. Angus has a BA (Hons) in Politics and International Relations from the University of Reading.



# GOODBODY BOTANICALS PRODUCTS



CBD Oil  
5% (500mg)



Peppermint  
CBD Oil  
20% (2000mg)



Peppermint CBD  
Oil  
15% (1500mg)



CBD Oil  
2.5% (250mg)



CBD Oil  
10% (1000mg)



CBD Soft gels  
30 x 10mg



CBD Balm  
1% (300mg)



CBD Gummies  
14 x 10mg





# GOODBODY WELLNESS VITAMIN D RANGE



Orange and  
Lemons with  
Vitamin D CBD Oil



Peppermint with  
Vitamin D CBD Oil